Treatment of idiopathic pulmonary fibrosis: Is there anything new?
- 9 June 2005
- journal article
- review article
- Published by Wiley in Respirology
- Vol. 10 (3) , 284-289
Abstract
Abstract: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic fibrosing interstitial pneumonia of unknown aetiology and is associated with the histological picture of usual interstitial pneumonia. Treatment in most cases is unsatisfactory and the prognosis remains poor. There is insufficient evidence to suggest that any treatment, apart from lung transplantation, improves survival or halts disease progression for IPF patients. Data on treatment response are limited by the paucity of clinical trails, the lack of homogenous clinical features, the small number of patients, and the absence of histological and radiological documentation in many cases. Anti‐inflammatory medications such as corticosteroids, azathioprine and cyclophosphamide remain the commonly used medications. More recently, it has been proposed that IPF is a primary fibrotic disease rather than an inflammatory condition. Antifibrotic agents such as colchicine, pirfenidone and interferon‐gamma (IFN‐γ) have been tried. However, a recent placebo‐controlled trial has failed to demonstrate a significant effect of IFN‐γ on disease progression, lung function or quality of life in IPF patients, though a clinically significant survival benefit of the drug could not be ruled out.Keywords
This publication has 45 references indexed in Scilit:
- Idiopathic Pulmonary FibrosisDrugs, 2004
- Open-label Compassionate Use One Year-treatment with Pirfenidone to Patients with Chronic Pulmonary Fibrosis.Internal Medicine, 2002
- Occupational and Environmental Risk Factors for Idiopathic Pulmonary Fibrosis: A Multicenter Case-Control StudyAmerican Journal of Epidemiology, 2000
- A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 1999
- In search of a cause of cryptogenic fibrosing alveolitis (CFA): one initiating factor or many?Thorax, 1998
- In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseasesClinical and Experimental Immunology, 1992
- Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis.Thorax, 1989
- Colchicine-Induced Modulation of Collagenase in Human Skin Fibroblast Cultures. I. Stimulation of Enzyme Synthesis in Normal CellsJournal of Investigative Dermatology, 1982
- Alveolitis: the key to the interstitial lung disorders.Thorax, 1982
- Natural History and Treated Course of Usual and Desquamative Interstitial PneumoniaNew England Journal of Medicine, 1978